Solventum's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Solventum (SOLV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Solventum vs Its Competitors
- TTM: Trailing 12-month revenue of 8,310M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+6.3% annualized vs trailing 12 months).
- Scale: Solventum ranks #15 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 1.4% of industry market cap.
- Peer revenue share: Solventum accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SOLV Sales vs. its Competitors, Q2 2026
Solventum generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 2.2% for Solventum. Solventum's share of combined industry revenue moved from 2.13% to 1.89%, a loss of 0.24 percentage points.
Solventum's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Solventum Corporation | Yes | No | No | - |
| High-Confidence Competitors (12) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SOLV Stock Performance relative to its Competitors
SOLV Stock Performance relative to High-Confidence Competitors
SOLV Stock Performance relative to Similar-Size Competitors
SOLV Stock Performance relative to Similar Growth & Profitability Competitors
Solventum's Comment on Competition and Industry Peers
Solventum's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Becton Dickinson | Named by the company | 85% |
| Dentsply Sirona | Named by the company | 85% |
| Ivoclar | Named by the company | 85% |
| Smith & Nephew | Named by the company | 85% |
| Sanara Medtech Inc | Named by the company | 85% |
| Coloplast | Named by the company | 85% |
| Hartmann | Named by the company | 85% |
| Medline | Named by the company | 85% |
| MDF Instruments | Named by the company | 85% |
| BSN | Named by the company | 85% |
| Envista | Named by the company | 85% |
| Medaxis | Named by the company | 85% |
| Steris | Named by the company | 85% |
| Align Technology | Named by the company | 85% |
| Convatec | Named by the company | 85% |
| ICU Medical | Named by the company | 85% |
| Mölnlycke | Named by the company | 85% |
| Cardinal Health | Named by the company | 85% |
| Fortive | Named by the company | 85% |
| Medela | Named by the company | 85% |
| Straumann | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Solventum's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Solventum's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Solventum Corporation | Infection Prevention and Surgical Solutions 36.72 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).